(Stroke. 2000;31:936.)
© 2000 American Heart Association, Inc.
Original Contributions |
C242T Polymorphism of NADPH Oxidase p22 PHOX Gene and Ischemic Cerebrovascular Disease in the Japanese Population
From the Departments of Neurology (D.I., N.T., Y.F.), Laboratory Medicine (M.M., K.W.), and Hematology (M.M.) and the Health Center (T.Y., I.S.), School of Medicine, Keio University, Tokyo, Japan.
Correspondence to Daisuke Ito, MD, Department of Neurology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Background and Purpose—Superoxide has been implicated in the pathogenesis of ischemic stroke and atherosclerosis. NADPH oxidase, a major source of superoxide generation in neutrophils and the vascular system, plays a critical role in ischemic injury and atherogenesis. Recently, an association between the C242T polymorphism of p22 PHOX, an essential component of NADPH oxidase, and coronary artery disease (CAD) has been reported in several studies. To investigate the relationship between the C242T polymorphism of p22 PHOX and ischemic cerebrovascular disease (CVD), we conducted a case-control study.
Methods—We recruited 226 CVD patients (atherothrombotic infarction, lacunar infarction, and transient ischemic attack) and 301 control subjects and analyzed C242T polymorphism of p22 PHOX by detection of restriction fragment length polymorphism.
Results—The TC+TT genotype frequencies in the CVD group
and control group were 21.7% and 13.3%, respectively, and the
prevalence of the TC+TT genotype was significantly higher in
the CVD patients (
2=6.477, P=0.01, OR
1.81, 95% CI 1.15 to 2.86). Analysis by CVD subtypes showed
that the OR for the TC+TT genotype was higher in the CVD
patients with atherothrombotic infarction than in those with lacunar
infarction and transient ischemic attack.
Conclusions—The C242T polymorphism of the NADPH oxidase p22 PHOX gene is a novel pathogenetic risk factor for CVD.
Key Words: cerebrovascular disorders • oxygen radical • polymorphism (genetics) • risk factors • stroke, ischemic
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
It is now widely accepted that oxygen free radicals contribute to the pathogenesis of ischemic cerebrovascular disease.1 2 3 4 Reperfusion of the ischemic brain results in a massive increase in oxygen free radicals and can exacerbate ischemic injury. The antioxidant enzymes superoxide dismutase and catalase reduce ischemic damage, and overexpression of superoxide dismutase in transgenic mice protects neuron from ischemic/reperfusion injury.1 2 3 4 Although several distinct oxygen free radicals can be generated from a number of different sources, neutrophils and phagocytes, which are observed in ischemic brain tissue, are particularly able to produce oxygen free radicals and have thus been implicated in ischemic injury.5 Recently, the NADPH oxidase system was reported to be essential for superoxide formation in neutrophils and phagocytes and to play a major role in mediating ischemic injury in the brain.6
In addition, it was reported that the major source of superoxide in the vascular system, composed of vascular smooth muscle cells (VSMCs) and endothelial cells, is the NADPH oxidase system, and this enzyme system is involved in atherogenesis.7 8 9 A recent study indicated that p22 PHOX, which is a component of NADPH oxidase, is expressed in VSMCs and serves as a critical component of superoxide-generating vascular NADPH oxidase and regulates vascular hypertrophy.10
The NADPH oxidase system is a group of plasma membrane–associated enzymes, comprising 5 components: p40 PHOX, p47 PHOX, p22 PHOX, and p91 PHOX.11 Three genetic polymorphisms have been reported in the coding sequence of the p22 PHOX gene.12 Among them, the C242T polymorphism results in an amino acid dimorphism (His/Tyr) at residue 72, which is located in putative heme-binding sites. Because the histidine residue is a candidate for the coordinating ligand of the heme prosthetic group of cytochrome b, this polymorphism has been suggested to be directly associated with the function of p22 PHOX.
There is considerable controversy about whether the C242T polymorphism is associated with a risk of thrombotic risk. Originally, Inoue et al13 reported that the T allele of this polymorphism is associated with a reduced risk of coronary artery disease (CAD) and is a novel genetic risk factor for CAD. However, recent large studies14 15 found no evidence of any association between this polymorphism and CAD. In contrast, an Australian group16 found that the TT+TC genotype is associated with an increased risk for CAD in a young male population.
The primary aim of this study was to determine whether the C242T polymorphism of the p22 PHOX gene is associated with cerebrovascular disease.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
We recruited 226 Japanese patients aged
70 years with
symptomatic ischemic cerebrovascular disease (CVD)
from Keio University Hospital in Tokyo and 301 control subjects. The
CVD patients with cardioembolic cerebral infarction and cerebral
hemorrhage were excluded. Control subjects were those who
visited for regular check-ups; those who had a clinical history of
cerebrovascular disease or myocardial infarction or
peripheral vascular diseases were excluded. Informed
consent was obtained from all subjects after a full explanation of the
study. In all CVD patients, brain CT and/or MRI were performed. MR
angiography and/or extracranial duplex ultrasonography were available
in >80% of the CVD patients. On the basis of Classification of
Cerebrovascular Diseases III, reported from the committee established
by the National Institute of Neurological Disorders and
Stroke,17 the CVD patients were divided into 3 clinical
categories: atherothrombotic infarction, lacunar infarction, and
transient ischemic attack (TIA). Hypertension was defined as systolic blood pressure >140 mm Hg and/or diastolic pressure >90 mm Hg or current treatment with antihypertensive drugs. Smoking was defined as a current smoking. Hypercholesterolemia was defined as a cholesterol level >220 mg/dL or current treatment with a cholesterol-lowering drug.
DNA Procedure
Whole blood was collected into sodium citrate tubes. A direct
DNA amplification kit (Shimadzu Co), which enabled us to amplify
DNA from whole blood without DNA extraction steps, was used in this
study. Amplification of the 353-bp fragment of the p22 PHOX
gene was performed essentially as previously
described,13 with the 5' primer
5'-TGCTTGTGGGTAAACCAAGG-3' and 3' primer 5'-GGAAAAACACTGAGGTAAGTG-3'. A
0.5-µL quantity of whole blood, 25 pmol of each primer, 400
µmol/L of each deoxy nucleotide triphosphate, 2.5 µL of
5xAmpdirect, 2.5 µL of 5xAmp Addition-1, and 1.25 U Taq polymerase
(TOYOBO Co) and water were added to the reaction to achieve a total
volume of 25 µL. The polymerase chain reaction (PCR) consisted of 1
cycle of 15 minutes at 85°C and 3 minutes at 95°C, 40 cycles of 1
minute at 55°C, 1 minute at 55°C, and 1 minute at 55°C, followed
by 7 minutes at 72°C in a Gene Amp PCR system 2400 (Perkin Elmer).
The 353-bp PCR product (4 µL) was cleaved in appropriate buffer
with 10 U of Rsa 1 restriction enzyme (New England Biolabs). The DNA
fragments were separated by electrophoresis through a 2% agarose gel
containing 0.5 µg/mL of ethidium bromide and visualized under
ultraviolet light. Digestion of the PCR products yielded bands of
353 bp in CC-homozygotes, 193 and 160 bp in TT-homozygotes, and all 3
bands in the heterozygotes.
Statistical Analysis
The differences in the frequencies of p22 PHOX
genotypes and other risk factors were analyzed by
2 test. Mean ages between 2 groups were
compared with the use of the Student t test. Multiple
logistic regression methods were conducted to control for possible
confounding factors. Associations and differences with values of
P<0.05 were considered significant. All statistical
analyses were performed with Statview (version 5.0 for Windows;
SAS Institute).
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
A total of 226 CVD patients and 301 control subjects were recruited for the study. Table 1
shows the prevalence of selected risk factors for CVD among the CVD
patients and the controls. There were no significant differences in age
or sex between the 2 groups. The risk factors hypertension, diabetes,
and smoking were significantly more common in the CVD
patients.
|
The distributions of genotypes and the frequencies of
alleles of the p22 PHOX gene polymorphism in the
control and CVD groups are shown in Table 2. The genotype frequencies in
both groups were in Hardy-Weinberg equilibrium. The T allele
frequency in the CVD group was 0.12 compared with 0.07 in the control
group, and the prevalence of the TC+TT genotype was
significantly higher in the CVD than in the control group
(2=6.477, P=0.01). The crude OR of
the CT+TT genotype versus the CC genotype between the
CVD patients and control subjects was 1.81 (95% CI, 1.15 to 2.86;
Table 3). In addition, analysis
by CVD subtypes showed the OR of the TC+TT genotype to be
highest in the CVD patients with atherothrombotic infarction, followed
by those with lacunar infarction, and then TIA (2.22, 1.71, and 1.37,
respectively).
|
|
We next analyzed whether the prevalences of well-established
acquired risk factors for stroke (hypertension, diabetes mellitus, and
smoking) were different among the genotypes of p22
PHOX. As shown in Table 4,
there was no significant difference in the frequency of these factors
between CC and CT+TT genotypes, suggesting that the
polymorphism is not directly linked to those risk factors. In the
multiple logistic regression analysis, hypertension, diabetes
mellitus, smoking, and this polymorphism were included as
independent variables. The ORs and probability value were as
follows: hypertension (OR 5.03, P<0.001), diabetes mellitus
(OR 4.41, P<0.001), smoking (OR 2.27, P<0.001),
and genotypes of p22 PHOX (CC+CT, OR 1.88,
P=0.02). Although the OR of this polymorphism was lower
than those of well-established risk factors (hypertension, diabetes
mellitus, and smoking), this analysis revealed that the
presence of T allele was one of the independent risk factors for
the development of CVD.
|
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
In this study, the frequency of the T allele was found to be significantly higher in the CVD patients than in controls, and among CVD subtypes, T allele frequency was highest in atherothrombotic infarction. These findings indicate that the polymorphism itself may be functionally involved in the increased risk or that it may be a marker of linkage disequilibrium with relevant functional changes. Our data also show the absence of any statistical association between TIA and this polymorphism. TIA is caused by several distinct mechanisms, including thrombosis, embolism, vasospasm, vasculitis, and hemodynamic crisis. Therefore, the association between TIA and this polymorphism may be lower than in other types of CVD. Another possibility is that the C allele in TIA may have a protective effect on ischemic injury and prevent progression to infarction.
Numerous neutrophils and phagocytes have been observed within the parenchyma of ischemic brain tissue.5 These cells induce tissue damage by releasing proteolytic enzymes and generating free radicals. Walder et al6 demonstrated that ischemic injury is reduced in mice whose central nervous system and peripheral leukocytes lack a functional NADPH oxidase, suggesting that superoxide generated by this enzyme system plays a major role in mediating ischemic injury in the brain. Furthermore, the NADPH oxidase system reportedly contributes to the pathogenesis of atherosclerosis and thrombotic disease.9 Recent findings have confirmed that NADPH oxidase is present in a variety of nonphagocytic cells, including endothelial cells and VSMCs. Mohazzab and colleagues8 have demonstrated by chemiluminescence that NADPH oxidase is a major source of superoxide in cultured endothelial cells. The hypertrophic agent angiotensin II increases superoxide production in VSMCs by activating NADPH oxidase.7 This enzyme appears to be the major source of superoxide in this cell type and plays an important role in vascular hypertrophy. Ushio-Fukai et al10 demonstrated that inhibition of p22 PHOX mRNA expression by stable transfection of antisense cDNA into VSMCs decreases superoxide production and angiotensin II-induced vascular hypertrophy, which suggests that p22 PHOX is a critical component of the superoxide-generating vascular NADPH oxidase system and that it is involved in vascular hypertrophy.
Published data on the association between the C242T polymorphism of
p22 PHOX and the risk of CAD are conflicting. Inoue et
al13 first investigated the association of this p22
PHOX polymorphism with CAD in 201 Japanese patients.
They found the T allele in the C242T polymorphism to be
significantly more frequent in the control subjects than in the CAD
patients, which indicates that the T allele might have a protective
effect in terms of coronary risk. Two more recent studies,
14 15 however, have failed to show any association
between this polymorphism and CAD. In contrast, an Australian
study16 in which 689 Australian Caucasians were
analyzed reported that the T allele tended to be more
prevalent in the CAD patient and that the difference was statistically
significant among young male patients aged 45 years.
The present study is the first to show evidence of an association between CVD and the C242T polymorphism of p22 PHOX. We demonstrated a significant by higher frequency of the T allele in the CVD patients than in the controls. Our finding supports the results of the Australian study of a young population,16 but conflicts with those of the Japanese study reported by Inoue et al.13 No studies have yet examined the functional effects of the C242T polymorphism on the activity and regulation of NADPH oxidase. This polymorphism of the putative heme-binding site in the p22 PHOX gene may have different effects on NADPH oxidase in the central nervous system and the cardiovascular system and have opposite effects in CVD and CAD. Further studies that examine the functions of NADPH oxidase in different p22 PHOX genotypes will establish whether this reported association is causal.
Received October 13, 1999; revision received January 3, 2000; accepted January 3, 2000.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
-
Liu TH, Beckman HS, Freeman BA, Hogan EL, Hsu CY.
Polyethylene glycol-conjugated superoxide dismutase and catalase reduce
ischemic brain injury. Am J Physiol. 1989;256:H589–H593.
[Abstract/Free Full Text] -
Imaizumi S, Woolworht V, Fishman RA, Chan PH.
Liposome-entrapped superoxide dismutase reduces cerebral infarction in
cerebral ischemia in rats. Stroke. 1990;21:1312–1317.
[Abstract/Free Full Text] -
He YY, HSU CY, Ezrin AM, Miller MS. Polyethylene
glycol-conjugated superoxide dismutase in focal cerebral
ischemia reperfusion. Am J Physiol. 1993;265:H252–H256.
[Abstract/Free Full Text] -
Chan PH. Role of oxidants in ischemic brain
damage. Stroke. 1996;27:1124–1129.
[Abstract/Free Full Text] -
Del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland
BR, Chang CM. Polymorphonuclear leukocytes occlusion and
reperfusion in baboon. Stroke. 1991;22:1276–1283.
[Abstract/Free Full Text] - Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, Thomas GR. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke. 1997;8:2252–2258.
-
Griendling KK, Minieri CA, Ollerenshaw JD, Alexander
W. Angiotensin II stimulates NADH and NADPH oxidase
activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148.
[Abstract/Free Full Text] -
Mohazzab KM, Kaminski PM, Wolin MS. NADH
oxidoreductase is a major source of superoxide anion in bovine
coronary artery endothelium. Am J
Physiol. 1994;266:H2568–H2572.
[Abstract/Free Full Text] - Harrison DG. Endothelial function and oxidant stress. Clin Cardiol. 1997;20:II-11–II-17.
- Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;38:23317–23321.
- Babior BM. NADPH oxidase: an update. Blood. 1999 93;1464–1476.
- Dinauer MC, Pierce EA, Bruns GA, Curnutte JT, Orkin SH. Human neutrophil cytochrome b light chain (p22-phox). Gene structure, chromosomal location, and mutation in cytochrome-negative autosomal recessive chronic granulomatous disease. J Clin Invest. 1990;86:1729–1737.
-
Inoue N, Kawashima S, Kanazawa K, Yamada S, Akita H,
Yokoyama M. Polymorphism of the NADH/NADPH oxidase p22
phox gene in patients with coronary artery disease.
Circulation. 1998;97:135–137.
[Abstract/Free Full Text] - Gardemann A, Mages P, Katz N, Tillmanns H, Haberbosch W. The p22 phox A640G gene polymorphism but not the C242T gene variation is associated with coronary heart disease in younger individuals. Atherosclerosis. 1999;145:315–323.[Medline] [Order article via Infotrieve]
- Li A, Prasad A, Mincemoyer R, Satorius C, Epstein N, Finkel T, Quyyumi AA. Relationship of the C242T p22phox gene polymorphism to angiographic coronary artery disease and endothelial function. Am J Med Genet.. 1999;86:57–61.[Medline] [Order article via Infotrieve]
- Cai H, Duarte N, Wilcken DE, Wang XL. NADH/NADPH oxidase p22 phox C242T polymorphism and coronary artery disease in the Australian population. Eur J Clin Invest. 1999;29:744–788.[Medline] [Order article via Infotrieve]
-
Ad Hoc Committee of National Institute of Neurological
Disorders and Stroke. Classification of Cerebrovascular Disease III.
Stroke. 1990;21:637–676.
[Free Full Text]
This article has been cited by other articles:
 |
|
 |
|
  M. Arca, B. Conti, A. Montali, P. Pignatelli, F. Campagna, F. Barilla, G. Tanzilli, R. Verna, A. Vestri, C. Gaudio, et al. C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 752 - 757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Bedard and K.-H. Krause The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology Physiol Rev, January 1, 2007; 87(1): 245 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Leopold and J. Loscalzo Oxidative Enzymopathies and Vascular Disease Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1332 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ago, T. Kitazono, J. Kuroda, Y. Kumai, M. Kamouchi, H. Ooboshi, M. Wakisaka, T. Kawahara, K. Rokutan, S. Ibayashi, et al. NAD(P)H Oxidases in Rat Basilar Arterial Endothelial Cells Stroke, May 1, 2005; 36(5): 1040 - 1046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsunaga-Irie, T. Maruyama, Y. Yamamoto, Y. Motohashi, H. Hirose, A. Shimada, M. Murata, and T. Saruta Relation Between Development of Nephropathy and the p22phox C242T and Receptor for Advanced Glycation End Product G1704T Gene Polymorphisms in Type 2 Diabetic Patients Diabetes Care, February 1, 2004; 27(2): 303 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Voetsch and J. Loscalzo Genetic Determinants of Arterial Thrombosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 216 - 229. [Abstract] [Full Text]
|
|
|
|
|
|
T. M. Paravicini, S. Chrissobolis, G. R. Drummond, and C. G. Sobey Increased NADPH-Oxidase Activity and Nox4 Expression During Chronic Hypertension Is Associated With Enhanced Cerebral Vasodilatation to NADPH In Vivo Stroke, February 1, 2004; 35(2): 584 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Hodgkinson, B. A. Millward, and A. G. Demaine Association of the p22phox Component of NAD(P)H Oxidase With Susceptibility to Diabetic Nephropathy in Patients With Type 1 Diabetes Diabetes Care, November 1, 2003; 26(11): 3111 - 3115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hayaishi-Okano, Y. Yamasaki, Y. Kajimoto, K.'y. Sakamoto, K. Ohtoshi, N. Katakami, D. Kawamori, T. Miyatsuka, M. Hatazaki, Y. Hazama, et al. Association of NAD(P)H Oxidase p22 phox Gene Variation With Advanced Carotid Atherosclerosis in Japanese Type 2 Diabetes Diabetes Care, February 1, 2003; 26(2): 458 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Meschia Addressing the Heterogeneity of the Ischemic Stroke Phenotype in Human Genetics Research Stroke, December 1, 2002; 33(12): 2770 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Van Heerebeek, C Meischl, W Stooker, C J L M Meijer, H W M Niessen, and D Roos NADPH oxidase(s): new source(s) of reactive oxygen species in the vascular system? J. Clin. Pathol., August 1, 2002; 55(8): 561 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Ito, N Tanahashi, M Murata, H Sato, I Saito, K Watanabe, and Y Fukuuchi Notch3 gene polymorphism and ischaemic cerebrovascular disease J. Neurol. Neurosurg. Psychiatry, March 1, 2002; 72(3): 382 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Whitehead and G. A. FitzGerald Twenty-First Century Phox: Not Yet Ready for Widespread Screening Circulation, January 2, 2001; 103(1): 7 - 9. [Full Text] [PDF]
|
|
|
|
|
|
D. Ito, M. Murata, N. Tanahashi, H. Sato, A. Sonoda, I. Saito, K. Watanabe, and Y. Fukuuchi Polymorphism in the Promoter of Lipopolysaccharide Receptor CD14 and Ischemic Cerebrovascular Disease Stroke, November 1, 2000; 31(11): 2661 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Guzik, N. E. J. West, E. Black, D. McDonald, C. Ratnatunga, R. Pillai, and K. M. Channon Functional Effect of the C242T Polymorphism in the NAD(P)H Oxidase p22phox Gene on Vascular Superoxide Production in Atherosclerosis Circulation, October 10, 2000; 102(15): 1744 - 1747. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||